Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase ii trial

Journal of Urology

Volumn 189, Issue 1 SUPPL, 2013, Pages

  Fizazi, Karim ^a   Bosserman, Linda ^b   Gao, Guozhi ^c   Skacel, Tomas ^c   Markus, Richard ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Wilshire Oncology Medical Group   (United States)

^c AMGEN INC   (United States)

Author keywords

denosumab; osteoclasts; prostatic neoplasms; RANK ligand; urinary N telopeptide of type I collagen human

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; DENOSUMAB; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE DISEASE; BONE LESION; BONE METASTASIS; BONE PAIN; CALCIUM BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DIARRHEA; DRUG EFFICACY; FEVER; HEMATURIA; HUMAN; HYPOCALCEMIA; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; OSTEOLYSIS; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 84870862207     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.022     Document Type: Article

References (20)

1. World Health Organization Health statistics and health information systems: Revised Global Burden of Disease (GBD) 2002 estimates http://www.who.int/healthinfo/bodgbd2002revised/en/index.html Accessed May 15, 2008
2. R.E. Coleman Skeletal complications of malignancy Cancer 80 1997 1588
3. J.E. Brown, R.J. Cook, P. Major Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 2005 59
4. D.L. Lacey, H.L. Tan, J. Lu Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 2000 435
5. K. Fizazi, J. Yang, S. Peleg Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts Clin Cancer Res 9 2003 2587
6. A.B. Ross, T.A. Bateman, P.J. Kostenuik The effects of osteoprotegerin on the mechanical properties of rat bone J Mater Sci Mater Med 12 2001 583
7. T. Sone, T. Tamada, Y. Jo Analysis of three-dimensional microarchitecture and degree of mineralization in bone metastases from prostate cancer using synchrotron microcomputed tomography Bone 35 2004 432
8. J. Yang, K. Fizazi, S. Peleg Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway Cancer Res 61 2001 5652
9. N.W. Clarke, J. McClure, N.J. George Morphometric evidence for bone resorption and replacement in prostate cancer Br J Urol 68 1991 74
10. R.B. Martin Skeletal biology R.B. Martin, D.B. Burr, N.A. Sharkey, Skeletal Tissue Mechanics 1998 Springer New York 29 78
11. J. Pfeilschifter, I.J. Diel Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 2000 1570
12. J.E. Brown, C.S. Thomson, S.P. Ellis Bone resorption predicts for skeletal complications in metastatic bone disease Br J Cancer 89 2003 2031
13. M. Aapro, P.A. Abrahamsson, J.J. Body Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420
14. J.J. Body, T. Facon, R.E. Coleman A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 12 2006 1221
15. K. Fizazi, A. Lipton, X. Mariette Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 2009 1564
16. M.R. Smith, R.J. Cook, R. Coleman Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer Urology 70 2007 315
17. A. Lipton, G.G. Steger, J. Figueroa Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy Clin Cancer Res 14 2008 6690
18. K. Fizazi, P. Beuzeboc, J. Lumbroso Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 27 2009 2429
19. K. Fizazi The role of Src in prostate cancer Ann Oncol 18 2007 1765
20. M.A. Carducci, A. Jimeno Targeting bone metastasis in prostate cancer with endothelin receptor antagonists Clin Cancer Res 12 2006 6296s